The Contraceptives Market size was valued at USD 26.29 billion in 2023 and is expected to reach USD 44.71 billion by 2032 with a growing CAGR of 6.10% over the forecast period of 2024-2032.
The report identifies changing patterns of preference and switching trends for contraceptive methods as well as how access to health care and health policy is shifting to affect the availability and choice of contraception. This study also focuses on the contribution of technological advancements and digital health solutions to improved product delivery and accessibility. Moreover, it addresses demographic and socioeconomic trends that impact market demand by highlighting age, income, and education levels influencing consumer preferences in choosing specific types of contraceptives.
Get more information on Contraceptives Market - Request Sample Report
Drivers
The contraceptive market is expanding due to growing awareness, improved accessibility, and strong government support.
Around 1.1 billion women across the globe need contraception, according to the United Nations Population Fund (UNFPA), and 257 million have no access to modern contraceptive methods. Market growth has been aided by an upsurge in long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and implants. For example, in the U.S. LARCs represented over 10% of contraceptive use in 2023. Moreover, programs such as India’s National Family Planning Program and Europe’s subsidized contraception policies have reduced the cost and improved the availability of methods. The proliferation of telehealth services and online pharmacies, like Nurx and Planned Parenthood Direct, has facilitated access to contraceptives for consumers who do not want to see a healthcare provider, as well.
Restraints
Cultural barriers, side effects, and limited access to contraception in rural areas
Even with increasing awareness, cultural and religious barriers still limit contraceptive adoption and use in the Middle East, Africa, and parts of Asia. According to estimates from the Guttmacher Institute, the rate of pregnancies that arise unpredictably is as high as 43%. The stigma of contraceptives and the absence of availability leads to this. The hormonal contraceptives, such as birth control pills and implants, often have side effects, including weight gain, mood swings, and the risk of blood clots, which restrains their use. The major problem with birth control acceptance in rural areas is the lack of access to healthcare facilities. For example, in sub-Saharan Africa, only 24% of married women use modern contraceptives as opposed to over 70% in Western Europe.
Opportunities
Innovating contraceptive technology indicates big opportunities within the market.
With newly developed non-hormonal contraceptives, such as Phexxi (a vaginal pH regulator), freedom is given to opt for a hormone-free alternative. Also, ongoing research into male contraceptive pills and gels, such as Nestorone-Testosterone gel, is expected to change the face of the market. The rise of telemedicine and digital pharmacies bolstered accessibility further in areas where the option of an in-person healthcare visit is impossible. The telehealth contraception market in the U.S. grew by 35% in 2023, growing larger due to a rise in platforms such as Nurx, Hers, and Lemonaid Health. Also, some government-backed digital healthcare schemes, including France's free birth control for women aged under 26, are increasing further market growth.
Challenges
The contraceptive market is faced with many difficulties, especially due to both tough regulations and counterfeit products.
In several countries, new contraceptive drugs or devices take several years to gain approval, thus delaying market entry. For example, many countries require that a cooperative clinical trial test be conducted for the approval of new birth control methods. In the U.S. Counterfeit contraceptives represent an increasing concern in many developing areas, as much as up to 30% of contraceptive pills sold are purportedly counterfeit or substandard (as per the World Health Organization). These challenges need to be addressed by efforts that range from stricter regulations to global anti-counterfeiting measures, along with general awareness about genuine products for a safe and firm platform for growth in the market.
By Product
In 2023, the contraceptive devices segment accounted for the highest revenue share at 68.2%, further highlighting its dominant position in the market. Growth in this segment is attributed to increasing demand for LARCs and a desire for non-daily methods. The Condom segment took up the largest market share of contraceptive devices, both male and female because it remains the most commonly used form of contraception due to its affordability, accessibility, and the dual benefit of protection against STIs besides preventing pregnancy. Widespread availability and low cost of condoms also contribute to the dominance of the market.
The Contraceptive Drugs segment, although the smallest contributor to the market compared to contraceptive devices, is also expected to have promising growth over the forecast period. Within the Contraceptive Drugs segment, the largest category in 2023 was Contraceptive Pills, since oral contraceptives are still the most popular means of contraception for many users, given the convenience and ease of use and access. One more reason women across the globe favor contraceptive pills lies in their reasonably priced and readily available nature, thus becoming many a woman's preferred choice of contraceptive. Increasing innovations in hormone-based pills coupled with the incorporation of new types that have low side effects and thereby are beneficial will continue increasing demand for them as a result, acting like an important driving factor in contraceptive drugs. Among the contraceptive drugs, injectables are likely to grow at the fastest pace. Injectable contraceptives are gaining popularity because of their convenience and effectiveness in regions where long-acting contraceptives are not readily available. These injectables, usually administered every 3 months, provide a reliable alternative to daily pills and offer greater discretion and ease of use for women. The company can see an upward trend in the adoption of injectable contraceptives in emerging countries driven by improved and accessible health programs along with better networks for distribution.
In 2023, North America dominated the contraceptives market owing to high awareness about contraceptives, availability of a wide range of products, and strong government support for reproductive health initiatives. The U.S. leads in this market, due to an increasing uptake of long-acting reversible contraceptives (LARC) like contraceptive implants and intrauterine devices (IUDs). Furthermore, the rise of over-the-counter availability of emergency contraception has spurred the market growth.
Europe followed closely, with nations such as Germany, the U.K., and France pushing refundable contraception plans and campaigns to raise awareness about reproductive health. Hormonal contraceptives (such as patches, vaginal rings, and IUDs) continue to see strong demand from females due to positive healthcare policies and extensive insurance coverage. High acceptance of modern contraceptive methods within the region continues to drive expansion within the contraceptive market.
Supported by growing awareness, increased urbanization, and family planning policies initiated with governmental assistance in countries like India and China, the Asia-Pacific region is anticipated to witness the fastest growth. However cultural barriers and limited access in rural areas persist as significant obstacles. Factors such as increasing affordable contraceptive options, improving healthcare infrastructure, and the growth of telehealth services are expected to facilitate the growth of the market in this region.
Get Customized Report as per Your Business Requirement - Enquiry Now
Key Players and Product Offering by Them Related to Contraceptives
AbbVie, Inc. – Viramune
Afaxys, Inc. – Plan B One-Step
Agile Therapeutics – Twirla
Bayer AG – Mirena, Kyleena, Yaz, NuvaRing
Church & Dwight Co., Inc. – Trojan Condoms
Cupid Limited – Cupid Condoms
Johnson & Johnson Services, Inc. – Ortho Evra Patch
Organon Group of Companies – Nexplanon, NuvaRing
Pfizer Inc. – Sayana Press, Depo-Provera
Veru, Inc. – FC2 Female Condom
Amneal Pharmaceuticals – Alesse, Nordette
Cooper Companies – ParaGard (Copper IUD)
Evofem Biosciences – Phexxi
HRA Pharma – Ella
Maxwellia Ltd – Eden
Mayer Laboratories, Inc. – Glyde Condoms
Mithra Pharmaceuticals – Donesta
Reckitt Benckiser Group PLC – Durex Condoms
TherapeuticsMD, Inc. – Annovera
Recent Developments
In Feb 2025, the Albanese government introduced a USD 573.3 million women's health package, which includes the addition of the first new contraceptive pills to the PBS list in over 30 years. This initiative aims to improve access to healthcare for women across the country.
In March 2024, Governor Hochul announced that pharmacists in New York are now authorized to provide hormonal contraception without the need for a prescription. This new policy aims to improve access to contraceptive options and enhance reproductive healthcare across the state.
| Report Attributes | Details |
| Market Size in 2023 | USD 26.29 billion |
| Market Size by 2032 | USD 44.71 billion |
| CAGR | CAGR of 6.10% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product [Contraceptive Drugs (Contraceptive Pills, Patch, Injectables), Contraceptive Devices (Condom {Male Condom, Female Condom}, Subdermal Implants, Intrauterine Devices (IUDs) {Copper IUDs, Hormonal IUDs}, Vaginal Ring, Diaphragm)] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | AbbVie, Inc., Afaxys, Inc., Agile Therapeutics, Bayer AG, Church & Dwight Co., Inc., Cupid Limited, Johnson & Johnson Services, Inc., Organon Group of Companies, Pfizer Inc., Veru, Inc., Amneal Pharmaceuticals, Cooper Companies, Evofem Biosciences, HRA Pharma, Maxwellia Ltd, Mayer Laboratories, Inc., Mithra Pharmaceuticals, Reckitt Benckiser Group PLC, TherapeuticsMD, Inc. |
Contraceptives Market size was valued at USD 26.29 billion in 2023.
Contraceptive market is expected to reach at USD 44.71 billion by 2032
The cases of side effects due to the consumption of contraceptives medicines.
Rise in the government initiatives to prevent unwanted pregnancies.
Contraceptive market is divided into one types by product
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Contraceptive Method Preferences and Switching Trends
5.2 Healthcare Access and Policy Impact
5.3 Technological Innovations and Digital Health
5.4 Demographic and Socioeconomic Trends Impacting the Market
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Contraceptives Market Segmentation, By Product
7.1 Chapter Overview
7.2 Contraceptive Drugs
7.2.1 Contraceptive Drugs Market Trends Analysis (2020-2032)
7.2.2 Contraceptive Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Contraceptive Pills
7.2.3.1 Contraceptive Pills Market Trends Analysis (2020-2032)
7.2.3.2 Contraceptive Pills Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Patch
7.2.4.1 Patch Market Trends Analysis (2020-2032)
7.2.4.2 Patch Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Injectables
7.2.5.1 Injectables Market Trends Analysis (2020-2032)
7.2.5.2 Injectables Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Contraceptive Devices
7.3.1 Contraceptive Devices Market Trends Analysis (2020-2032)
7.3.2 Contraceptive Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Condom
7.3.3.1 Condom Market Trends Analysis (2020-2032)
7.3.3.2 Condom Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.3 Male Condom
7.3.3.3.1 Male Condom Market Trends Analysis (2020-2032)
7.3.3.3.2 Male Condom Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.3 Female Condom
7.3.3.4.1 Female Condom Market Trends Analysis (2020-2032)
7.3.3.4.2 Female Condom Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Subdermal Implants
7.3.4.1 Subdermal Implants Market Trends Analysis (2020-2032)
7.3.4.2 Subdermal Implants Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Intrauterine Devices (IUDs)
7.3.5.1 Intrauterine Devices (IUDs) Market Trends Analysis (2020-2032)
7.3.5.2 Intrauterine Devices (IUDs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.3 Copper IUDs
7.3.5.3.1 Copper IUDs Market Trends Analysis (2020-2032)
7.3.5.3.2 Copper IUDs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.4 Hormonal IUDs
7.3.5.4.1 Hormonal IUDs Market Trends Analysis (2020-2032)
7.3.5.4.2 Hormonal IUDs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Vaginal Ring
7.3.6.1 Vaginal Ring Market Trends Analysis (2020-2032)
7.3.6.2 Vaginal Ring Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.7 Diaphragm
7.3.7.1 Diaphragm Market Trends Analysis (2020-2032)
7.3.7.2 Diaphragm Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Regional Analysis
8.1 Chapter Overview
8.2 North America
8.2.1 Trends Analysis
8.2.2 North America Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.2.3 North America Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.2.2 USA
8.2.2.1 USA Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.2.3 Canada
8.2.3.1 Canada Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.2.4 Mexico
8.2.4.1 Mexico Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3 Europe
8.3.1 Eastern Europe
8.3.1.1 Trends Analysis
8.3.1.2 Eastern Europe Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.3.1.3 Eastern Europe Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.1.4 Poland
8.3.1.4.1 Poland Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.1.5 Romania
8.3.1.5.1 Romania Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.1.6 Hungary
10.3.1.8.1 Hungary Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.1.7 Turkey
8.3.1.7.1 Turkey Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.1.8 Rest of Eastern Europe
8.3.1.8.1 Rest of Eastern Europe Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2 Western Europe
8.3.2.1 Trends Analysis
8.3.2.2 Western Europe Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.3.2.3 Western Europe Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.4 Germany
8.3.2.4.1 Germany Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.5 France
8.3.2.5.1 France Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.6 UK
8.3.2.6.1 UK Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.7 Italy
8.3.2.7.1 Italy Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.8 Spain
8.3.2.8.1 Spain Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.9 Netherlands
8.3.2.9.1 Netherlands Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.10 Switzerland
8.3.2.10.1 Switzerland Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.11 Austria
8.3.2.11.1 Austria Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.3.2.12 Rest of Western Europe
8.3.2.12.1 Rest of Western Europe Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4 Asia Pacific
8.4.1 Trends Analysis
8.4.2 Asia Pacific Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.4.3 Asia Pacific Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.4 China
8.4.4.1 China Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.5 India
8.4.5.1 India Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.6 Japan
8.4.6.1 Japan Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.7 South Korea
8.4.7.1 South Korea Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.8 Vietnam
8.4.8.1 Vietnam Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.9 Singapore
8.4.9.1 Singapore Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.10 Australia
8.4.10.1 Australia Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.4.11 Rest of Asia Pacific
8.4.11.1 Rest of Asia Pacific Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5 Middle East and Africa
8.5.1 Middle East
8.5.1.1 Trends Analysis
8.5.1.2 Middle East Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.1.4 UAE
8.5.1.4.1 UAE Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.1.5 Egypt
8.5.1.5.1 Egypt Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.1.6 Saudi Arabia
8.5.1.6.1 Saudi Arabia Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.1.7 Qatar
8.5.1.7.1 Qatar Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.1.8 Rest of Middle East
8.5.1.8.1 Rest of Middle East Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.2 Africa
8.5.2.1 Trends Analysis
8.5.2.2 Africa Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.5.2.3 Africa Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.2.4 South Africa
8.5.2.4.1 South Africa Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.2.5 Nigeria
8.5.2.5.1 Nigeria Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.5.2.6 Rest of Africa
8.5.2.6.1 Rest of Africa Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.6 Latin America
8.6.1 Trends Analysis
8.6.2 Latin America Contraceptives Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
8.6.3 Latin America Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.6.4 Brazil
8.6.4.1 Brazil Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.6.5 Argentina
8.6.5.1 Argentina Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.6.6 Colombia
8.6.6.1 Colombia Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
8.6.7 Rest of Latin America
8.6.7.1 Rest of Latin America Contraceptives Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial
9.1.3 Products/ Services Offered
9.1.4 SWOT Analysis
9.2 Agile Therapeutics
9.2.1 Company Overview
9.2.2 Financial
9.2.3 Products/ Services Offered
9.2.4 SWOT Analysis
9.3 Church & Dwight Co., Inc.
9.3.1 Company Overview
9.3.2 Financial
9.3.3 Products/ Services Offered
9.3.4 SWOT Analysis
9.4 Cupid Limited
9.4.1 Company Overview
9.4.2 Financial
9.4.3 Products/ Services Offered
9.4.4 SWOT Analysis
9.5 Johnson & Johnson Services, Inc.
9.5.1 Company Overview
9.5.2 Financial
9.5.3 Products/ Services Offered
9.5.4 SWOT Analysis
9.6 Pfizer Inc.
9.6.1 Company Overview
9.6.2 Financial
9.6.3 Products/ Services Offered
9.6.4 SWOT Analysis
9.7 Amneal Pharmaceuticals
9.7.1 Company Overview
9.7.2 Financial
9.7.3 Products/ Services Offered
9.7.4 SWOT Analysis
9.8 Evofem Biosciences
9.8.1 Company Overview
9.8.2 Financial
9.8.3 Products/ Services Offered
9.8.4 SWOT Analysis
9.9 Mayer Laboratories, Inc.
9.9.1 Company Overview
9.9.2 Financial
9.9.3 Products/ Services Offered
9.9.4 SWOT Analysis
9.10 Reckitt Benckiser Group PLC
9.10.1 Company Overview
9.10.2 Financial
9.10.3 Products/ Services Offered
9.10.4 SWOT Analysis
10. Use Cases and Best Practices
11. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
Contraceptive Drugs
Contraceptive Pills
Patch
Injectables
Contraceptive Devices
Condom
Male Condom
Female Condom
Subdermal Implants
Intrauterine Devices (IUDs)
Copper IUDs
Hormonal IUDs
Vaginal Ring
Diaphragm
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Osteoporosis Treatment Market Size was valued at USD 13.28 billion in 2023, and is expected to reach USD 19.39 billion by 2032, and grow at a CAGR of 4.3% over the forecast period 2024-2032.
The Cosmetic Surgery Market Size, valued at USD 56.8 billion in 2023, is projected to reach USD 94.5 billion by 2032, growing at a 5.8% CAGR.
The Hip Replacement Market Size was valued at USD 7.7 Bn in 2023 and is expected to reach USD 11.20 Bn by 2031 and grow at a CAGR of 4.8% over the forecast period of 2024-2031.
The Healthcare Quality Management Market Size was valued at USD 3.31 billion in 2023 and is expected to reach USD 10.22 billion by 2032 and grow at a CAGR of 14.18% over the forecast period 2024-2032.
The mRNA Technology Market was valued at USD 35.67 billion in 2023 and is expected to reach USD 76.45 billion by 2032 with a growing CAGR of 8.88% over the forecast period of 2024-2032.
The Body Composition Analyzers Market Size was valued at USD 535.64 Mn in 2023 and is expected to reach USD 935.80 Mn by 2032 and grow at a CAGR of 6.42%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
